Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile

被引：0

作者：

Becker, C. ^{[1
]}

As-Sanie, S. ^{[2
]}

Zhai, D. ^{[3
]}

Perry, J. S. ^{[4
]}

Dynowski, K. ^{[5
]}

Wilk, K. ^{[6
]}

Wagman, R. B. ^{[4
]}

Rakov, V. G. ^{[7
]}

McClung, M. R. ^{[8
]}

机构：

[1] Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Headington Oxford, England

[2] Univ Michigan, Obstet & Gynecol, Ann Arbor, MI USA

[3] Sumitomo Pharma Amer Inc, Biostat, Cambridge, MA USA

[4] Sumitomo Pharma Amer Inc, Clin Dev, Cambridge, MA USA

[5] Med Ctr Postgrad Educ, Clin Res, Warsaw, Poland

[6] Boni Fratres Hosp, Obstet & Gynecol, Katowice, Poland

[7] Sumitomo Pharma Switzerland GmbH, Med Affairs, Basel, Switzerland

[8] Oregon Osteoporosis Ctr, Portland, OR USA

来源：

关键词：

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

P-308

引用

页数：2